Protalix BioTherapeutics, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Protalix BioTherapeutics, Inc. (PLX) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $1.31 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-12.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2020-03-12
- Protalix BioTherapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2017 was $1.31M, a 91.97% increase from fiscal 2016.
- Protalix BioTherapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2016 was $685.00K.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2017-12-31 | $1.31M 10-K · filed 2020-03-12 |
| 2016-12-31 | $685.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |